Clinical TrialsSernova's Phase 1/2 study results are indicative of the trial being on track to succeed and help de-risk any upcoming data readouts and subsequent studies.
Hypothyroidism MarketSubmission of an IND application for the Cell Pouch device in hypothyroidism could address a significant market opportunity estimated at approximately $2.2 billion.
Technology PotentialThe clear clinical benefit in T1D patients, particularly insulin dependence, speaks to the potential of the Cell Pouch device.